This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Techne (TECH) Lags Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Techne (TECH) delivered earnings and revenue surprises of -3.78% and 4.34%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Albireo Pharma (ALBO) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Albireo Pharma (ALBO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Solid Biosciences Inc. (SLDB) Q3 Earnings Expected to Decline
by Zacks Equity Research
Solid Biosciences Inc. (SLDB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in Store for Novartis (NVS) This Earnings Season?
by Zacks Equity Research
Investors will focus on the regular top and bottom-line numbers along with updates on the Sandoz spin-off when Novartis (NVS) reports third-quarter 2022 results.
Solid Biosciences Inc. (SLDB) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Solid Biosciences Inc. (SLDB) delivered earnings and revenue surprises of -4.76% and 77.27%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Femasys Inc. (FEMY) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Femasys Inc. (FEMY) delivered earnings and revenue surprises of 15.38% and 1%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
MannKind (MNKD) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
MannKind (MNKD) delivered earnings and revenue surprises of -22.22% and 15.68%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Solid Biosciences Inc. (SLDB) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Solid Biosciences Inc. (SLDB) delivered earnings and revenue surprises of -22.22% and 46.08%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Sanofi (SNY) Stock Outperforms Industry YTD: What Lies Ahead?
by Zacks Equity Research
Here we discuss some factors that have been driving Sanofi's (SNY) stock and its outlook for the future.
Alnylam's (ALNY) Vutrisiran NDA Faces Delay in FDA Decision
by Zacks Equity Research
The FDA needs time to review new information incorporated into Alnylam's (ALNY) vutrisiran NDA related to a new secondary packaging and labeling facility, which has been cited as a reason for the delay
Merck's (MRK) Pneumococcal Vaccine sBLA Faces FDA Delay
by Zacks Equity Research
Merck's (MRK) Vaxneuvance vaccine includes pneumococcal serotypes 22F and 33F, which are not included in the currently licensed 13-valent conjugate vaccines.
Solid Biosciences Inc. (SLDB) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Solid Biosciences Inc. (SLDB) delivered earnings and revenue surprises of 15% and 9.26%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
All You Need to Know About Solid Biosciences Inc. (SLDB) Rating Upgrade to Buy
by Zacks Equity Research
Solid Biosciences Inc. (SLDB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
REGENXBIO (RGNX) DMD Gene Therapy Gets Orphan Drug Status
by Zacks Equity Research
REGENXBIO (RGNX) is developing a gene therapy candidate, RGX-202, for treating DMD, which is currently in the pre-clinical stage. An IND application is expected by the end of 2021.
Solid Biosciences Inc. (SLDB) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Solid Biosciences Inc. (SLDB) delivered earnings and revenue surprises of 15.79% and 7.18%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Sarepta (SRPT) Begins Pivotal Study on DMD Gene Therapy
by Zacks Equity Research
Sarepta (SRPT) is developing its lead gene therapy candidate, SRP-9001, as a potential one-time treatment for DMD.
Implied Volatility Surging for Solid Biosciences (SLDB) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Solid Biosciences (SLDB) stock based on the movements in the options market lately.
5 Gene Therapy Stocks Back in Focus on AbbVie/Regenxbio Deal
by Kinjel Shah
The promising gene therapy approach is being evaluated for varied diseases, such as hemophilia, Duchenne muscular dystrophy (DMD), Parkinson's disease, eye disease, and cancer among others
Solid Biosciences Inc. (SLDB) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Solid Biosciences Inc. (SLDB) delivered earnings and revenue surprises of 5.56% and 14.10%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Sarepta (SRPT) Rises on Robust DMD Gene Therapy Study Data
by Zacks Equity Research
Sarepta's (SRPT) lead gene therapy candidate, SRP-9001, demonstrates robust improvement in expression of micro-dystrophin protein in DMD patients after 12 weeks of treatment.
Should You Buy Solid Biosciences (SLDB) Ahead of Earnings?
by Radhika Saraogi
Solid Biosciences (SLDB) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
CuriosityStream (CURI) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
CuriosityStream's (CURI) fourth-quarter 2020 results are expected to reflect expanding subscriber base, driven by strong factual content portfolio.
Implied Volatility Surging for Solid Biosciences (SLDB) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Solid Biosciences (SLDB) stock based on the movements in the options market lately.
Solid Biosciences (SLDB) Announces DMD Study Data, Stock Down
by Zacks Equity Research
Solid Biosciences' (SLDB) lead gene therapy candidate achieves positive improvements in DMD patients. However, it fails to cheer investors.
Sarepta (SRPT) Inks New Gene Editing Research Collaboration
by Zacks Equity Research
Sarepta (SRPT) signs agreement with Genevant to develop lipid nanoparticle-based gene editing medicines targeting neuromuscular indications.